Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Shulman

Showing results (11-20 of 119) with videos related to

Pageof 12
Sort By:
Pharmacoeconomics|December 10, 1991
The reimbursement factor in pharmaceutical regulation: rebates, cost-effectiveness, and practice guidelinesS R Shulman
Pharmacoeconomics|December 9, 1993
The Canadian Patented Medicine Prices Review Board. New rules and new statusS R Shulman
Blood|December 1, 1977
Splenomegaly after intensive treatment of hemophiliaN R Shulman
The American Journal of Medical Technology|September 1, 1972
Complement fixation techniques for measuring hepatitis associated antigen and antibodyN R Shulman
Hospital Formulary|December 11, 1987
Drug refusal must include legal definition of competenceS R Shulman
Pharmacoeconomics|December 8, 1997
Pharmacy benefit management companies (PBMs). Why should we be interested?S R Shulman
Pharmacoeconomics|December 9, 1995
Healthcare reform in the US. Momentum shifts from federal to state governmentsS R Shulman
The New England Journal of Medicine|August 24, 1972
Immunologic reactions to drugsN R Shulman
Leadership in Health Services = Leadership Dans Les Services De Sante|August 6, 1993
Report from The Centre for Quality in Governance. Criteria for choosing a chief executive officerE Preiss, R Shulman
Leadership in Health Services = Leadership Dans Les Services De Sante|October 5, 1992
Hospital boards: not just for showR Shulman, P Gamble
Pageof 12

Showing results (11-20 of 119) with videos related to

Sort By:
Pageof 12
Pharmacoeconomics|December 10, 1991
The reimbursement factor in pharmaceutical regulation: rebates, cost-effectiveness, and practice guidelinesS R Shulman
Pharmacoeconomics|December 9, 1993
The Canadian Patented Medicine Prices Review Board. New rules and new statusS R Shulman
Blood|December 1, 1977
Splenomegaly after intensive treatment of hemophiliaN R Shulman
The American Journal of Medical Technology|September 1, 1972
Complement fixation techniques for measuring hepatitis associated antigen and antibodyN R Shulman
Hospital Formulary|December 11, 1987
Drug refusal must include legal definition of competenceS R Shulman
Pharmacoeconomics|December 8, 1997
Pharmacy benefit management companies (PBMs). Why should we be interested?S R Shulman
Pharmacoeconomics|December 9, 1995
Healthcare reform in the US. Momentum shifts from federal to state governmentsS R Shulman
The New England Journal of Medicine|August 24, 1972
Immunologic reactions to drugsN R Shulman
Leadership in Health Services = Leadership Dans Les Services De Sante|August 6, 1993
Report from The Centre for Quality in Governance. Criteria for choosing a chief executive officerE Preiss, R Shulman
Leadership in Health Services = Leadership Dans Les Services De Sante|October 5, 1992
Hospital boards: not just for showR Shulman, P Gamble
Pageof 12